Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

How Positive Cretostimogene Trial Updates And Leadership Moves At CG Oncology (CGON) Have Changed Its Investment Story [Yahoo! Finance]

CG Oncology, Inc. - Common stock (CGON) 
Company Research Source: Yahoo! Finance
CG Oncology has reported positive topline data from its BOND-003 and CORE-008 trials of investigational oncolytic immunotherapy cretostimogene in high-risk non-muscle invasive bladder cancer, showing encouraging high-grade event-free survival, strong complete response rates and a generally well-tolerated safety profile that will be presented at the 26th Society of Urologic Oncology meeting. Show less Read more
Impact Snapshot
Event Time:
CGON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for CGON alerts
Opt-in for
CGON alerts

from News Quantified
Opt-in for
CGON alerts

from News Quantified